The chromatin-remodeling enzymes BRG1 and CHD4 antagonistically regulate vascular Wnt signaling

Molecular and Cellular Biology

Volumn 32, Issue 7, 2012, Pages 1312-1320

  Curtis, Carol D ^a   Griffin, Courtney T ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BRG1 PROTEIN; CHD4 PROTEIN; DNA BINDING PROTEIN; LITHIUM CHLORIDE; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR PITX2; UNCLASSIFIED DRUG; WNT PROTEIN; BETA CATENIN; HELICASE; MI 2BETA PROTEIN, MOUSE; MI-2BETA PROTEIN, MOUSE; NUCLEAR PROTEIN; SMARCA4 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE DELETION; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VASCULAR ENDOTHELIUM; YOLK SAC; ANEMIA; ANIMAL; CELL CULTURE; CELL LINE; CHROMATIN; CYTOLOGY; ENDOTHELIUM CELL; ERYTHROCYTE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANEMIA; ANIMALS; BETA CATENIN; CELL LINE; CELLS, CULTURED; CHROMATIN; DNA HELICASES; ENDOTHELIAL CELLS; ERYTHROCYTES; GENE DELETION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; MICE; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT PROTEINS; YOLK SAC;

EID: 84859957578     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06222-11     Document Type: Article

References (40)

1. Bultman S, et al. 2000. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol. Cell 6:1287-1295.
2. Bultman SJ, Gebuhr TC, Magnuson T. 2005. A Brg1 mutation that uncouples ATPase activity from chromatin remodeling reveals an essential role for SWI/SNF-related complexes in beta-globin expression and erythroid development. Genes Dev. 19:2849-2861.
3. Chappell JC, Bautch VL. 2010. Vascular development: genetic mechanisms and links to vascular disease. Curr. Top. Dev. Biol. 90:43-72.
4. Corada M, et al. 2010. The Wnt/beta-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. Dev. Cell 18:938-949.
5. Dejana E. 2010. The role of wnt signaling in physiological and pathological angiogenesis. Circ. Res. 107:943-952.
6. Eferl R, et al. 1999. Functions of c-Jun in liver and heart development. J. Cell Biol. 145:1049-1061.
7. Gage PJ, Suh H, Camper SA. 1999. Dosage requirement of Pitx2 for development of multiple organs. Development 126:4643-4651.
8. Gao H, et al. 2009. Opposing effects of SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5. Proc. Natl. Acad. Sci. U. S. A. 106:11258-11263.
9. Gebuhr TC, et al. 2003. The role of Brg1, a catalytic subunit of mammalian chromatin-remodeling complexes, in T cell development. J. Exp. Med. 198:1937-1949.
10. Gregory GD, et al. 2010. FOG1 requires NuRD to promote hematopoiesis and maintain lineage fidelity within the megakaryocytic-erythroid compartment. Blood 115:2156-2166.
11. Griffin CT, Brennan J, Magnuson T. 2008. The chromatin-remodeling enzyme BRG1 plays an essential role in primitive erythropoiesis and vascular development. Development 135:493-500.
12. Griffin CT, Curtis CD, Davis RB, Muthukumar V, Magnuson T. 2011. The chromatin-remodeling enzyme BRG1 modulates vascular Wnt signaling at two levels. Proc. Natl. Acad. Sci. U. S. A. 108:2282-2287.
13. Hang CT, et al. 2010. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 466:62-67.
14. Hargreaves DC, Crabtree GR. 2011. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 21:396-420.
15. Ho L, Crabtree GR. 2010. Chromatin remodelling during development. Nature 463:474-484.
16. Indra AK, et al. 2005. Temporally controlled targeted somatic mutagenesis in embryonic surface ectoderm and fetal epidermal keratinocytes unveils two distinct developmental functions of BRG1 in limb morphogenesis and skin barrier formation. Development 132:4533-4544.
17. Jochum W, Passegue E, Wagner EF. 2001. AP-1 in mouse development and tumorigenesis. Oncogene 20:2401-2412.
18. Kashiwagi M, Morgan BA, Georgopoulos K. 2007. The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development 134:1571-1582.
19. Kisanuki YY, et al. 2001. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 230:230-242.
20. Kwon CS, Wagner D. 2007. Unwinding chromatin for development and growth: a few genes at a time. Trends Genet. 23:403-412.
21. Lin CR, et al. 1999. Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis. Nature 401:279-282.
22. Liu W, Selever J, Lu MF, Martin JF. 2003. Genetic dissection of Pitx2 in craniofacial development uncovers new functions in branchial arch morphogenesis, late aspects of tooth morphogenesis and cell migration. Development 130:6375-6385.
23. Lu MF, Pressman C, Dyer R, Johnson RL, Martin JF. 1999. Function of Rieger syndrome gene in left-right asymmetry and craniofacial development. Nature 401:276-278.
24. Lucitti JL, et al. 2007. Vascular remodeling of the mouse yolk sac requires hemodynamic force. Development 134:3317-3326.
25. MacDonald BT, Tamai K, He X. 2009. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17:9-26.
26. Murakami M, et al. 2008. The FGF system has a key role in regulating vascular integrity. J. Clin. Invest. 118:3355-3366.
27. Nilasena DS, Trieu EP, Targoff IN. 1995. Analysis of the Mi-2 autoantigen of dermatomyositis. Arthritis Rheum. 38:123-128.
28. Pestronk A, Schmidt RE, Choksi R. 2010. Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve 42:53-61.
29. Ramirez J, Hagman J. 2009. The Mi-2/NuRD complex: a critical epigenetic regulator of hematopoietic development, differentiation and cancer. Epigenetics 4:532-536.
30. Ramirez-Carrozzi VR, et al. 2006. Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev. 20:282-296.
31. Reyes JC, et al. 1998. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). EMBO J. 17:6979-6991.
32. Stankunas K, et al. 2008. Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. Dev. Cell 14: 298-311.
33. Takeuchi JK, et al. 2011. Chromatin remodelling complex dosage modulates transcription factor function in heart development. Nat. Commun. 2:187.
34. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. 1998. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature 395:917-921.
35. Wang SJ, Greer P, Auerbach R. 1996. Isolation and propagation of yolk-sac-derived endothelial cells from a hypervascular transgenic mouse expressing a gain-of-function fps/fes proto-oncogene. In Vitro Cell. Dev. Biol. Anim. 32:292-299.
36. Williams CJ, et al. 2004. The chromatin remodeler Mi-2beta is required for CD4 expression and T cell development. Immunity 20:719-733.
37. Wu JI, Lessard J, Crabtree GR. 2009. Understanding the words of chromatin regulation. Cell 136:200-206.
38. Wu JI, et al. 2007. Regulation of dendritic development by neuronspecific chromatin remodeling complexes. Neuron 56:94-108.
39. Zhang J, et al. 2012. Harnessing of the nucleosome-remodelingdeacetylase complex controls lymphocyte development and prevents leukemogenesis. Nat. Immunol. 13:86-94.
40. Zhang M, et al. 2011. SWI/SNF complexes containing Brahma or Brahma-related gene 1 play distinct roles in smooth muscle development. Mol. Cell. Biol. 31:2618-2631.